Low 21-gene expression score associated with low risk of breast cancer recurrence
the ONA take:
Patients with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer and a favorable 21-gene expression assay score had very low rates of disease recurrence at 5 years with endocrine therapy alone, initial results of the TAILORx study published online ahead of print in The New England Journal of Medicine have shown.
For the study, 10,253 eligible women with breast cancer were enrolled. Of those, 1,626 women had a recurrence score of 0 to 10 who were assigned to receive endocrine therapy alone without chemotherapy.
Results showed that 5-year invasive disease-free survival rate was 93.8% (95% CI: 92.4, 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI: 98.7, 99.6), and the rate of freedom from recurrence at a distant or local-regional site was 98.7%. Researchers found that the overall survival rate was 98.0% (95% CI: 97.1, 98.6).
"The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice," said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.
Patients with HER2-negative, axillary node-negative breast cancer and favorable 21-gene expression assay score had low rates of recurrence.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|